Genomics England analysed 2,500+ breast cancer genomes in a Lifebit federated environment.
Population-scale genomic analysis faced huge data volumes, long pipelines and rising cost. Lifebit's federated TRE let Genomics England, Cambridge and the NHS work on one governed dataset without moving data. The page reports 27% of patients with actionable findings, 70% faster runtime and 50% lower compute cost, with results published in Lancet Oncology.
Lifebit is a federated data and trusted research environment vendor, used by pharma and public health bodies to analyse sensitive genomic and clinical data in place
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by Lifebit on its own site — read the original case study on lifebit.ai ↗
Note: Public-sector research customer rather than a pharma sponsor.
Related use cases
- 01Boehringer Ingelheim analysed UK Biobank and Genomics England data in place using Lifebit's federated research environment.
- 02Flatiron Health federated global oncology data analysis across jurisdictions with Lifebit.
- 03Lupus Research Alliance harmonised molecular and clinical data from 9+ CROs on a Lifebit federated platform.
- 04How Bioventus evolved their commercial strategy with real world data and intelligence
- 05Clarivate and CLEO diagnostics are making early detection of ovarian cancer a reality
- 06Making informed investment decisions (Attracting breakthrough innovations from academic research) - SPRIND case study